Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for "Global Equity Strategy". The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% during the quarter, compared to a 13.90% return for the MSCI World Index, gross dividends reinvested. The Composite remained ahead for the year-to-date period through June 30, 2026, gaining 19.95% versus 9.94% for the benchmark, driven by strong performance from IT holdings, particularly AI-related companies and memory semiconductor suppliers. Please review the Fund's top five holdings to gain insights into its key selections for 2026.

In its second-quarter 2026 investor letter, Polaris Global Equity Strategy highlighted Cytokinetics, Incorporated (NASDAQ:CYTK). Cytokinetics, Incorporated (NASDAQ:CYTK) is a US-based biopharmaceutical company that focuses on developing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases. On September 22, 2026, Cytokinetics, Incorporated (NASDAQ:CYTK) closed at $67.59 per share. Over the past month, Cytokinetics, Incorporated (NASDAQ:CYTK) declined 14.66%, and its shares gained 39.97% over the past 52 weeks. Cytokinetics, Incorporated (NASDAQ:CYTK) has a market capitalization of $9.4 billion, and its stock has traded within a 52-week range of $47.22 to $88.31.

Polaris Global Equity Strategy stated the following regarding Cytokinetics, Incorporated (NASDAQ:CYTK) in its Q2 2026 investor letter

"We added Cytokinetics, Incorporated (NASDAQ:CYTK) to our portfolio, a U.S. biopharma company with FDA approval for Myqorzo for hypertrophic cardiomyopathy; Myqorzo is seen as superior to Bristol Myers Squibb's Camzyos, offering better symptom relief with simpler dosing."

Cytokinetics, Incorporated (NASDAQ:CYTK) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 78 hedge fund portfolios held Cytokinetics, Incorporated (NASDAQ:CYTK) at the end of the second quarter which was 67 in the previous quarter. While we acknowledge the potential of Cytokinetics, Incorporated (NASDAQ:CYTK) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Cytokinetics, Incorporated (NASDAQ:CYTK) and highlighted late-stage trial data supporting aficamten for a genetic heart disease with no current treatments. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

This article is originally published at Insider Monkey.